Antengene Secures Australian Approval for Phase I Autoimmune Disease Study
Antengene Corporation has received clinical trial approval in Australia to commence the Phase I ATTRACT study, investigating its ATG-201 therapy for B cell-related autoimmune diseases.
Antengene Corporation announced it has received approval from Australian authorities to initiate the Phase I ATTRACT study. This clinical trial will evaluate the safety and tolerability of ATG-201, a bispecific T cell engager (TCE) therapy targeting CD19 and CD3.
The study aims to assess the potential of ATG-201 in treating patients with B cell-related autoimmune conditions. This marks an expansion for Antengene into the autoimmune disease therapeutic area.
The approval allows Antengene to explore its TCE technology beyond its established oncology focus. The company is dedicated to developing novel therapies for unmet medical needs.
Results from the Phase I study are expected to provide initial data on ATG-201's pharmacokinetic and pharmacodynamic profiles, guiding future development strategies.